The reduction in Ca125 biomarker provides an early sign that a treatment regimen is effective in combating ovarian cancer. At the reported doses, toxic effects observed were generally mild and ProLindac displayed none of the acute neurotoxicity associated with other approved DACH platinum compounds.
Stephen Seiler, president and CEO of Access, said: “We are very pleased by the activity and safety of ProLindac in the early cohorts of the ovarian cancer trial. Even as we continue dose escalation in the current trial, existing results have given us sufficient confidence to move forward with the execution of additional development plans for ProLindac and we have already commenced manufacturing drug supply for several further clinical trials, including combination trials, which we plan to commence beginning next year.”